JAK2 V617F: implications for thrombosis in myeloproliferative diseases.

Autor: Hexner EO

Publikováno v: Current Opinion in Hematology; 2007 Sep, Vol. 14 Issue 5, p450-454, 5p

Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis.

Autor: Tefferi A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN., Barosi G; Department of Hematology, Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Pavia, Italy., Passamonti F; Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Hernandez-Boluda JC; Haematology Department, Hospital Clínico Universitario, Instituto de Investigación Sanitaria, Valencia, Spain., Bose P; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Ellis M; Department of Hematology, Hematology Institute, Meir Medical Center, Tel Aviv University, Tel Aviv, Israel., Gangat N; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN., Garcia JS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Gisslinger H; Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria., Gotlib J; Department of Hematology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA., Guglielmelli P; Department of Hematology, Center of Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy., Gupta V; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Harrison C; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Hexner EO; Cell Therapy and Transplant Program, Division of Hematology-Oncology, Department of Medicine, Philadelphia, PA., Hobbs GS; Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA., Kiladjian JJ; Department of Hematology, Centre d'Investigations Cliniques Hôpital Saint-Louis, Université Paris Cité, Paris, France., Koschmieder S; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Aachen, Germany., Kroger N; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Kuykendall AT; Department of Hematology, H. Lee Moffitt Cancer Center, Tampa, FL., Loscocco GG; Department of Hematology, Center of Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy., Mascarenhas J; Division of Hematology and Oncology, Department of Internal Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Masarova L; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Mesa R; Department of Hematology, Levine Cancer Institute, Charlotte, NC., Mora B; Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Odenike O; Department of Hematology, Leukemia Program, University of Chicago Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL., Oh ST; Division of Hematology, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO., Pardanani A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN., Patel A; Department of Hematology, Leukemia Program, University of Chicago Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL., Pemmaraju N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Rambaldi A; Department of Oncology and Hematology, University of Milan, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Rampal R; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY., Sirhan S; Department of Hematology, Jewish General Hospital, McGill University, Montreal, QC, Canada., Szuber N; Department of Hematology, Maisonneuve-Rosemont Hospital, University of Montreal, Quebec, QC, Canada., Talpaz M; Department of Hematology-Oncology, University of Michigan, Ann Arbor, MI., Vachhani PJ; Department of Medicine, Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, AL., Vannucchi AM; Department of Hematology, Center of Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy., Barbui T; Department of Hematology, FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.

Publikováno v: Blood [Blood] 2024 Oct 24; Vol. 144 (17), pp. 1813-1820.

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.

Autor: Akahoshi Y; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Spyrou N; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Weber D; Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany., Aguayo-Hiraldo P; Division of Bone Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA., Ayuk F; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Chanswangphuwana C; Division of Hematology and Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand., Choe HK; Division of Hematology, Blood and Marrow Transplant Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Eder M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Etra AM; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Grupp SA; Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA.; Department of Pediatrics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Hexner EO; Department of Medicine and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Hogan WJ; Division of Hematology, Mayo Clinic, Rochester, MN., Kitko CL; Pediatric Hematology/Oncology Division, Vanderbilt University Medical Center, Nashville, TN., Kraus S; Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany., Al Malki MM; City of Hope, Duarte, CA., Merli P; Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Qayed M; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Reshef R; Division of Hematology/Oncology and Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY., Schechter T; Division of Hematology/Oncology/BMT, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada., Ullrich E; Department of Pediatrics, Experimental Immunology and Cell Therapy, Goethe University Frankfurt, Frankfurt, Germany., Vasova I; Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany., Wölfl M; Department of Pediatrics, University Hospital of Würzburg, Würzburg, Germany., Zeiser R; Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Baez J; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Beheshti R; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Eng G; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Gleich S; Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany., Katsivelos N; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Kowalyk S; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Morales G; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Young R; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Chen YB; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA., Nakamura R; City of Hope, Duarte, CA., Levine JE; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Ferrara JLM; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Publikováno v: Blood [Blood] 2024 Aug 29; Vol. 144 (9), pp. 1010-1021.

The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.

Autor: DeFilipp Z; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA., Kim HT; Department of Data Science, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA., Spyrou N; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Katsivelos N; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Kowalyk S; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Eng G; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Kasikis S; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Beheshti R; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Baez J; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Akahoshi Y; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Ayuk F; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Choe H; Division of Hematology, James Cancer Center, The Ohio State University, Columbus, OH., Etra A; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Grupp SA; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA., Hexner EO; Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA., Hogan WJ; Division of Hematology, Mayo Clinic, Rochester, MN., Kitko CL; Pediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, TN., Qayed M; Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA., Reshef R; Blood and Marrow Transplantation Program, Columbia University Medical Center, New York, NY., Vasova I; Department of Internal Medicine 5, Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Zeiser R; Department of Medicine I - Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Young R; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Holler E; Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany., Ferrara JLM; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Nakamura R; Hematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA., Levine JE; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Chen YB; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA.

Publikováno v: Blood advances [Blood Adv] 2024 Jul 09; Vol. 8 (13), pp. 3488-3496.

Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.

Autor: Bagley SJ; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. sbagley@pennmedicine.upenn.edu.; Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. sbagley@pennmedicine.upenn.edu., Logun M; Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Fraietta JA; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Wang X; Department of Neuroscience, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Desai AS; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Bagley LJ; Department of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Nabavizadeh A; Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Jarocha D; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Martins R; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Maloney E; Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Lledo L; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Stein C; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Marshall A; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Leskowitz R; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Jadlowsky JK; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Christensen S; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Oner BS; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Plesa G; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Brennan A; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Gonzalez V; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Chen F; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Sun Y; Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Neuroscience, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Gladney W; Kite Pharma, a Gilead Company, Santa Monica, CA, USA., Barrett D; Kite Pharma, a Gilead Company, Santa Monica, CA, USA., Nasrallah MP; Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Hwang WT; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Ming GL; Department of Neuroscience, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Institute for Regenerative Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Song H; Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Neuroscience, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Institute for Regenerative Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Siegel DL; Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., June CH; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Hexner EO; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Binder ZA; Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., O'Rourke DM; Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. donald.orourke@pennmedicine.upenn.edu.; Department of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. donald.orourke@pennmedicine.upenn.edu.; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. donald.orourke@pennmedicine.upenn.edu.

Publikováno v: Nature medicine [Nat Med] 2024 May; Vol. 30 (5), pp. 1320-1329. Date of Electronic Publication: 2024 Mar 13.